Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma
Targovax, a Norwegian immune-oncology company, said that its lead candidate ONCOS-102 has secured the fast track designation from the US Food and Drug Administration (FDA) for malignant pleural mesothelioma. The FDA fast track status to ONCOS-102 was granted based on promising pre-clinical and clinical efficacy related to broad immune activation observed so far, said Targovax. […]
Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) in adults. The approval is for Opdivo 360 mg every three weeks with 1 mg/kg every six weeks (injections for intravenous use) of […]
Continue reading …
Business News Today
- Önusberget wind farm : GE Renewable Energy bags contract for 137 turbines
- El Campo project : Ely Gold Royalties acquires heavy rare earth project in California
- NER-II transmission project : IndiGrid to acquire NER-II from Sterlite Power for $630m
- Wipro to acquire management and technology consultancy Capco for $1.4bn
- Dabur India launches Dabur Vatika Select shampoo range
- KKR to acquire majority stake in Integrated Specialty Coverages
- Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab
- Adani Ports to acquire stake in Gangavaram Port for $270m
- Infosys to create 500 new jobs in Calgary amid Canadian expansion
- Boston Scientific to acquire Lumenis surgical business for $1bn